IC31®: Enhance the immunogenicity of your vaccine with the IC31® adjuvant
IC31® is a synthetic vaccine adjuvant with a well-defined mechanism of action (TLR9/MyD88 pathway)1.
It has demonstrated good activity at the clinical level with an induction of a potent type 1 immune response, including strong and long-lasting CD4+ T-cell responses, and a favorable safety/tolerability profile in all clinical studies performed so far.
IC31® has been partnered with various vaccine companies and research institutes, including GSK, Sanofi Pasteur, the Statens Serum Institut, and Aeras.
It has been tested in the following indications:
* Clinical data
|| Proof of Concept
||Tuberculosis*, chlamydia trachomatis, chlamydia pneumoniae, streptococcus pneumoniae, meningitis B, helicobacter pylori, borrelia
|| Viral pathogens
||Influenza*, hepatitis B*, dengue, HSV-2, Japanese encephalitis, HIV, CMV
Under a strategic alliance agreement signed in 2007, Novartis Vaccines (now GSK Vaccines) received a license for the use of IC31® in selected new vaccines.
In 2015, Valneva granted an exclusive worldwide license to Altimmune for the clinical development of hepatitis B vaccines in combination with the IC31® adjuvant.
In the field of tuberculosis, three vaccine candidates formulated with Valneva’s IC31® adjuvant have been tested in Phase 1 and 22,3
clinical trials. The Statens Serum Institut’s novel vaccine candidate, H56/IC31®, is currently in a Phase 2 study to evaluate the reduction of tuberculosis recurrence in adults post-treatment4
The use of the IC31® adjuvant in oncology is under investigation.
Selected IC31® publications
IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems - Lingnau K & al., Expert Rev Vaccines. 2007 Oct;6(5):741-6.2
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial - Reither K & al., PLoS One. 2014 Dec 9;9(12):e114602.3
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG
Revaccination - Nemes E & al, N Engl J Med. 2018 Jul 12;379(2):138-149.4
Dose Optimization of H56:IC31 Vaccine for TB Endemic Populations: A Double-Blind, Placebo-Controlled, Dose-Selection Trial - Suliman & al., Am J Respir Crit Care Med. 2018 Aug 9.
For any request or need for additional information please contact:Camille GeeraertManager Business DevelopmentT
+ 33 228 07 37 10E bd(at)valneva.com